TAYSHA GENE THERAPIES, INC.

Profile

Company Names

TAYSHA GENE THERAPIES, INC.

Addresses

3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX 75247

7318 MORTON STREET, DALLAS, TX 75209

Phone Numbers

(214) 612-0000
212.551.8702

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2019

State Incorporated:

DELAWARE

Total Amount Raised:

$293,952,583.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2023-08-16 
$149,952,767.00 
$149,997,018.00 
$44,251.00 
Equity 
3
2022-10-21 
$30,000,000.00 
$30,000,000.00 
$0.00 
Equity 
2
2020-07-02 
$95,999,816.00 
$95,999,816.00 
$0.00 
Equity 
1
2020-03-04 
$18,000,000.00 
$30,000,000.00 
$12,000,000.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
KAMRAN 
 
ALAM 
EXECUTIVE OFFICER
AQUINOX PHARMACEUTICALS (USA) INC   |  AQUINOX PHARMACEUTICALS INC   |  TAYSHA GENE THERAPIES, INC.   |  NOTCH THERAPEUTICS, INC.
PHILLIP 
 
DONENBERG 
DIRECTOR
TAYSHA GENE THERAPIES, INC.
PHILLIP 
B. 
DONENBERG 
DIRECTOR
EOSHEALTH, INC.   |  TAYSHA GENE THERAPIES, INC.   |  TECTONIC THERAPEUTIC, INC.   |  SENSEI BIOTHERAPEUTICS, INC.
PAUL 
B. 
MANNING 
DIRECTOR
DOVA PHARMACEUTICALS, INC.   |  XALUD THERAPEUTICS, INC.   |  ARCHERDX, INC.   |  TAYSHA GENE THERAPIES, INC.   |  LIQUIDIA CORP   |  VERRICA PHARMACEUTICALS INC.
SUKUMAR 
 
NAGENDRAN 
DIRECTOR, EXECUTIVE OFFICER
AVEXIS, INC.   |  SOLID BIOSCIENCES INC.   |  TAYSHA GENE THERAPIES, INC.   |  SALIOGEN THERAPEUTICS, INC.   |  AMLOGENYX INC.
SEAN 
 
NOLAN 
DIRECTOR
AVEXIS, INC.   |  AFFINIA THERAPEUTICS INC.   |  TAYSHA GENE THERAPIES, INC.
SEAN 
P. 
NOLAN 
DIRECTOR, EXECUTIVE OFFICER
ISTARI ONCOLOGY, INC.   |  TAYSHA GENE THERAPIES, INC.
SUYASH 
 
PRASAD 
EXECUTIVE OFFICER
TAYSHA GENE THERAPIES, INC.
KATHLEEN 
 
REAPE 
DIRECTOR
TAYSHA GENE THERAPIES, INC.
LAURA 
 
SEPP-LORENZINO 
DIRECTOR
TAYSHA GENE THERAPIES, INC.
R. 
A. 
SESSION II 
EXECUTIVE OFFICER, DIRECTOR
TAYSHA GENE THERAPIES, INC.
R.A. 
 
SESSION II 
EXECUTIVE OFFICER, DIRECTOR
TAYSHA GENE THERAPIES, INC.
RA 
 
SESSION II 
EXECUTIVE OFFICER, DIRECTOR
RECODE THERAPEUTICS, INC.   |  TAYSHA GENE THERAPIES, INC.
SEAN 
 
STALFORT 
DIRECTOR
VERRICA PHARMACEUTICALS INC.   |  ADVANTAGENE, INC.   |  XALUD THERAPEUTICS, INC.   |  TOLERION, INC.   |  SALIOGEN THERAPEUTICS, INC.   |  TAYSHA GENE THERAPIES, INC.   |  BLUE MARLIN THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2023-08-25
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2023-08-16 
2022-11-07
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2022-10-21 
2020-08-18
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2020-07-02 
2020-05-04
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-03-04 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
JEFFERIES LLC
2347
NONE
NONE
CHARDON CAPITAL MARKETS LLC
120128